H. D. and W. Ra, The hallmarks of cancer, Cell, vol.100, issue.1, pp.55-70, 2000.

H. D. and W. Ra, Hallmarks of cancer: the next generation. Cell, 4 Mars, pp.646-74, 2011.

D. Gp, O. Lj, and S. Rd, The immunobiology of cancer immunosurveillance and immunoediting, Immunity, Aout, vol.21, pp.137-148, 2004.

M. D. , G. Mm, S. Schreiber-rd, and . Mj, New insights into cancer immunoediting and its three component phases?elimination, equilibrium and escape, Current Opinion in Immunology, vol.27, pp.16-65, 2014.

C. Ds and M. I. , Oncology meets immunology: The cancer immunity cycle, Immunity, vol.39, issue.1, pp.1-10

K. Cm, V. W. Swann-jb, Z. N. , R. Sj, O. Lj et al., Adaptative immunity maintains occult cancer in an equilibrium state, Nature, vol.450, pp.903-907, 2007.

S. Nd, Advances in the understanding of cancer immunotherapy, BJU International, vol.116, pp.321-329, 2015.

B. Gl and G. Wl, Immune escape mechanisms as a guide for cancer immunotherapy, Clinical Cancer Research, vol.15, issue.214, pp.687-692, 2015.

P. Gk and C. Lqm, The evolving role of immune checkpoint inhibitors in cancer treatment. The Oncologist, pp.812-822, 2015.

H. Y. , Q. H. , L. Y. , D. L. , and L. Y. Shi-g, The roles of regulatory B cells in cancer, Journal of immunology research, 2014.

N. Jp, L. Q. Lao-x, L. Dm, H. J. , L. Y. et al., B lymphocytes as effector cells in the immunotherapy of cancer, Journal of surgical oncology, vol.105, issue.4, pp.15-2012431

W. R. , M. J. , C. , and R. We, Myeloid derived suppressor cells ? a new therapeutic target in the treatment of cancer, Journal for immunotherapy of cancer, vol.1, pp.15-201310, 2013.

T. P. , C. , and R. We, Signaling pathways involved in MDSC regulation, Biochimica et Biophysica Acta, vol.1846, issue.1, pp.55-65, 2014.

P. Dm, The blockade of immune checkpoints in cancer immunotherapy, Nature Reviews Cancer, vol.12, pp.252-264, 2012.

S. E. , S. H. , G. P. , and C. Hx, Immune checkpoint inhibitors in clinical trials, Chinese Journal of Cancer, vol.33, issue.9, pp.434-444, 2014.

C. Wt and L. M. , Immunomodulation : checkpoint blockade etc, Neuro-Oncology, vol.17, pp.26-31, 2015.

S. Dl, D. Z. , L. A. , B. R. , and A. R. , Development of new immunotherapy treatments in different cancer types, Journal of Medecine and Life Juillet-Septembre, vol.2016, issue.93, pp.240-248

A. K. , S. E. , P. Gj, V. Den, and . Ajm, New developments in the treatment of metastatic melanoma : immune checkpoint inhibitors and targeted therapies, Anticancer Research, vol.34, issue.4, pp.1493-505, 2014.

B. Ei and D. A. , CTLA-4 and PD-1 pathways: Similarities, differences and implications of their inhibition, American Journal of Clinical Oncology, vol.39, issue.1, pp.98-106, 2016.

W. Ad, W. Mc, B. J. , and T. La, Signaling through CD28 and CTLA-4 controls two distinct forms of T cell anergy, Journal of Clinical Investigation, p.15

E. Jg and A. Jp, Cytotoxic T Lymphocyte Antigen-4 accumulation in the immunological synapse is regulated by TCR signal strength, Immunity, vol.16, issue.1, pp.23-35, 2002.

W. Jd and S. Y. , The mechanism of anti-CTLA-4 activity and the negative regulation of T-cell activation. The Oncologist, pp.2-9, 2008.

L. Jq, L. Xy, Y. Hq, Y. G. , L. Zq et al., Tumor-specific Th2 responses inhibit growth of CT26 colon-cancer cells in mice via converting intratumor regulatory T cells to Th9 cells Scientific Reports, pp.2-201510665

D. Mc, Z. Xn, L. Gn, and W. Jr, The Treg/Th17 paradigm in lung cancer, Journal of immunology Research, p.730380, 2014.

G. Kf, H. Hw, L. Sw, and F. Mb, Nuclear molecular imaging strategies in immune checkpoint inhibitor therapy, p.23, 2017.

H. Fs, O. Sj, D. Mcdermott, W. R. , S. J. et al., Improved survival with Ipilimumab in patients with metastatic melanoma, pp.363711-723, 2010.

F. A. , R. L. , G. M. , N. Sv, P. S. et al., Ipilimumab in advanced melanoma : reports of long-lasting responses, Melanoma research, vol.22, issue.3, pp.263-70, 2012.

M. Tr, C. T. , and C. Lm, Immune response to cancer therapy : Mounting an effective antitumor response and mechanisms of resistance. Trends in Cancer, pp.66-75, 2015.

G. Jf and J. Mn, CTLA-4 blockade in tumor models : an overview of preclinical and translational research. Cancer immunity, pp.22-20135

T. K. , K. Y. , U. T. , H. Y. , T. Mwl et al., Combination therapy of established tumors by antibodies targeting immune activating and suppressing molecules, The Journal of Immunology, issue.10, pp.1845493-501, 2010.

J. Mn, M. G. , G. E. , D. G. , L. F. et al., Synergy between chemotherapeutic agents and CTLA-4 blockade in preclinical tumor models, Cancer immunology, Immunotherapy, vol.62, pp.1533-1545, 2013.

P. Ba, T. Ds, K. S. , M. E. , and O. , Cooperativity of Staphylococcal aureus enterotoxin B superantigen, major histocompatibility complex class II, and CD80 for immunotherapy of advanced spontaneous metastases in a clinically relevant postoperative mouse breast cancer model, Cancer Research, vol.60, pp.15-2710, 2000.

C. Europeenne and P. D. , éthique de l'expérimentation animale, Directive n°2010/63 CEE, 22 Septembre, 2010.

N. Research, Guide for the care and use of laboratory animals, 1996.

G. El, C. Dl, K. N. , D. Cp, R. Es et al., Chapter 13: Anatomy. Dans Biology of the laboratory mouse, seconde édition, 1968.

T. Ba and . Chapter, Transplantable Syngeneic Rodent Tumors : Solid Tumors in Mice. Dans Tumor models in cancer research, seconde edition, 2010.

L. J. , C. , G. R. , G. Jj, C. Cl et al., Combined Nivolumab and Ipilimumab or monotherapy in untreated melanoma, pp.23-34, 2015.

W. Tl, The role of regulatory T cells in cancer immunology. ImmunoTargets and Therapy, pp.159-171, 2015.

T. Jr, K. Mj, S. Cp, F. J. , M. Tr et al., Into the eye of the cytokine storm, Microbiology and Molecular Biology Reviews, vol.76, issue.1, pp.16-32, 2012.

L. Wg, C. S. , G. M. , L. A. , W. B. et al., PD-L1 detection in tumors using [ 64 Cu]Atezolizumab with PET, Bioconjugate Chemistry, vol.27, issue.9, pp.2103-2110, 2016.

B. T. and C. Ma, 4-1BB agonists: Multi-potent potentiators of tumor immunity, Frontiers in Oncology, issue.5, p.117, 2015.

L. Hk, G. L. , C. E. , M. Jk, M. Mh et al., Gemcitabine directly inhibits myeloid derived suppressor cells n BALB/C mice, International Immunopharmacology, vol.9, issue.78, pp.900-909, 2009.

L. M. , J. X. , H. X. , P. L. , and Z. X. Zhao-y, Macrophages support splenic erythropoiesis in 4T1-tumor bearing mice, Plos One, issue.3, pp.10-0121921, 2015.

K. Aw, M. Jb, P. Ca, D. M. , K. M. et al., Tumor-induced MDSC act via remote control to inhibit L-selectindependent adaptive immunity in lymph nodes. eLife, p.17375, 2016.

R. En, H. Sv, R. Bw, L. Lake-ra, and . Wj, Programmed death Ligand 2 in cancer-induced immune suppression, Clinical and Developmental Immunology, p.656340, 2012.

U. S. Vivier-e, B. D. , C. C. , and B. L. , Targeting natural killer cells and natural killer T cells in cancer, Nature Reviews Immunology, vol.5, issue.4, pp.239-252, 2012.
DOI : 10.1038/nri1603

E. Ji, P. Simson-l, and . Cr, Th2-mediated anti-tumour immunity : friend of foe? Tissue Antigens, pp.1-11, 2007.

C. Jm, J. M. , C. F. , C. W. Kaplan-m, and Z. X. , New immunotherapies targeting the PD-1 pathways, Trends in Pharmacological Sciences, vol.36, issue.9, pp.587-95, 2015.

P. Sp and K. R. , PD-L1 expression as a predictive biomarker in cancer immunotherapy, Molecular Cancer Therapeutics, vol.14, issue.4, pp.847-56, 2015.

Z. W. , W. Jd, and C. L. Pd-l1, B7-H1) and PD-1 pathway blockade for cancer therapy: mechanisms, response biomarkers and combinations, Science Translational Medicine, vol.8, issue.328, 2016.